Although Trastuzumab, a monoclonal antibody targeting HER2, was approved by the FDA for the treatment of metastatic HER2+ breast cancer patients in 1998, minimizing its cardiac-related side effects has been the aim of several other trials 26,27. The gene discussed is ERBB2; the disease is breast carcinoma.